BrainStorm Cell Therapeutics is a biotechnology company based in Israel, focusing on the development of autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. The company's proprietary process, NurOwn, differentiates autologous mesenchymal stem cells into neurotrophic factor-secreting cells, offering a potential living drug delivery system for neurotrophic factors. The company has demonstrated proof-of-concept in various animal models and has completed successful clinical trials in Israel, with plans for Phase 3b clinical trials in the US. The company received a $16 million grant from the California Institute for Regenerative Medicine (CIRM) and support from the ALS Association for its Phase 3 trials.
Founded in 2004, BrainStorm operates in the biotechnology and healthcare industries. The latest investment was a $4.00M Post-IPO Equity investment on 27 June 2024, indicating continued investor interest in the company's innovative approach to treating neurodegenerative diseases. For more information, visit www.brainstorm-cell.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $4.00M | - | 27 Jun 2024 | |
| Post-IPO Equity | $7.50M | - | 17 Jul 2023 | |
| Grant | $1.50M | 1 | Israel Innovation Authority | 03 Apr 2020 |
| Post-IPO Equity | $10.00M | 1 |
|
06 Mar 2020 |
| Grant | $495.33K | 1 | National Multiple Sclerosis Society (NMSS) | 14 Nov 2019 |
No recent news or press coverage available for Brainstorm Cell Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
